Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts
Gilead's inflammation portfolio faces a packed back half of 2026 as the company works to expand beyond its HIV franchise.
Gilead Sciences
Gilead Sciences (NASDAQ: GILD) is a Foster City, California-based biopharmaceutical company with leadership in HIV (Biktarvy, Descovy), viral hepatitis (Sovaldi, Harvoni, Epclusa), and a growing oncology franchise (Trodelvy, Yescarta, Tecartus).
Company Info
Sector:Antiviral & Oncology Biopharmaceuticals
Headquarters:Foster City, California, USA
Founded:1987
Website:www.gilead.com/
Upcoming Milestones & Key Dates
2026-08-07
Earnings
Q2 2026 earnings
2026-09-15
Conference
ESMO presentations
Clinical Development Pipeline
Trodelvy + Keytruda
Target: TROP-2 ADC + PD-1Lenacapavir (Sunlenca)
Target: HIV capsidMagrolimab
Target: CD47Recent News
Gilead prevails in yearslong HIV drug innovation case
Gilead prevailed in a yearslong HIV drug innovation lawsuit after the California Supreme Court ruled drugmakers have no duty to innovate.
Gilead, MSD share data on once-weekly oral HIV treatment
Gilead and MSD shared data on a once-weekly oral HIV treatment that achieved high rates of viral suppression in Phase 3.
Gilead's TROP-2 Trodelvy, Keytruda combo win first-line FDA nods for breast cancer
Gilead Sciences' Trodelvy (TROP-2 ADC) combined with Merck's Keytruda (PD-1 inhibitor) received FDA approvals for first-line treatment of metastatic triple-negative breast cancer and HR+/HER2- breast cancer.
Leadership Team
Daniel O'Day
Chairman & Chief Executive Officer
Andrew Dickinson
Chief Financial Officer
Merdad Parsey
Chief Medical Officer
Careers & Job Openings